PMC:7156291 / 11039-17982
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
226 | 28-36 | Species | denotes | patients | Tax:9606 |
227 | 42-50 | Disease | denotes | COVID-19 | MESH:C000657245 |
229 | 87-104 | Disease | denotes | pulmonary lesions | MESH:D008171 |
233 | 1109-1117 | Species | denotes | patients | Tax:9606 |
234 | 1088-1105 | Disease | denotes | pulmonary lesions | MESH:D008171 |
235 | 1123-1131 | Disease | denotes | COVID-19 | MESH:C000657245 |
238 | 154-171 | Disease | denotes | pulmonary lesions | MESH:D008171 |
239 | 301-318 | Disease | denotes | pulmonary lesions | MESH:D008171 |
242 | 1505-1513 | Species | denotes | patients | Tax:9606 |
243 | 1519-1527 | Disease | denotes | COVID-19 | MESH:C000657245 |
251 | 2425-2433 | Species | denotes | patients | Tax:9606 |
252 | 2563-2570 | Species | denotes | patient | Tax:9606 |
253 | 2595-2602 | Species | denotes | patient | Tax:9606 |
254 | 2628-2635 | Species | denotes | patient | Tax:9606 |
255 | 2662-2669 | Species | denotes | patient | Tax:9606 |
256 | 2700-2707 | Species | denotes | patient | Tax:9606 |
257 | 2439-2447 | Disease | denotes | COVID-19 | MESH:C000657245 |
261 | 1738-1746 | Species | denotes | patients | Tax:9606 |
262 | 1840-1848 | Species | denotes | patients | Tax:9606 |
263 | 2055-2063 | Species | denotes | patients | Tax:9606 |
266 | 2750-2758 | Species | denotes | patients | Tax:9606 |
267 | 2764-2772 | Disease | denotes | COVID-19 | MESH:C000657245 |
272 | 2811-2819 | Species | denotes | patients | Tax:9606 |
273 | 2853-2861 | Species | denotes | patients | Tax:9606 |
274 | 2990-2997 | Species | denotes | patient | Tax:9606 |
275 | 3049-3057 | Species | denotes | patients | Tax:9606 |
278 | 4734-4750 | Disease | denotes | Pleural effusion | MESH:D010996 |
279 | 4787-4802 | Disease | denotes | Lymphadenopathy | MESH:D008206 |
282 | 3869-3877 | Species | denotes | patients | Tax:9606 |
283 | 3883-3891 | Disease | denotes | COVID-19 | MESH:C000657245 |
285 | 5111-5119 | Species | denotes | patients | Tax:9606 |
290 | 3192-3200 | Species | denotes | patients | Tax:9606 |
291 | 3368-3376 | Species | denotes | patients | Tax:9606 |
292 | 3522-3529 | Species | denotes | patient | Tax:9606 |
293 | 3740-3748 | Species | denotes | patients | Tax:9606 |
299 | 5160-5168 | Species | denotes | patients | Tax:9606 |
300 | 5265-5273 | Species | denotes | patients | Tax:9606 |
301 | 5370-5378 | Species | denotes | patients | Tax:9606 |
302 | 5173-5190 | Disease | denotes | pleural effusions | MESH:D010996 |
303 | 5208-5223 | Disease | denotes | lymphadenopathy | MESH:D008206 |
310 | 5549-5554 | Species | denotes | woman | Tax:9606 |
311 | 5589-5596 | Species | denotes | patient | Tax:9606 |
312 | 5574-5588 | Disease | denotes | COVID-infected | MESH:C000657245 |
313 | 5612-5617 | Disease | denotes | fever | MESH:D005334 |
314 | 5619-5624 | Disease | denotes | cough | MESH:D003371 |
315 | 5630-5643 | Disease | denotes | low back pain | MESH:D017116 |
320 | 6255-6262 | Species | denotes | patient | Tax:9606 |
321 | 6240-6254 | Disease | denotes | COVID-infected | MESH:C000657245 |
322 | 6278-6283 | Disease | denotes | fever | MESH:D005334 |
323 | 6288-6293 | Disease | denotes | cough | MESH:D003371 |
326 | 5494-5502 | Species | denotes | patients | Tax:9606 |
327 | 5508-5526 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T35 | 2403-2407 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T36 | 3781-3785 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T37 | 3845-3849 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T38 | 4905-4909 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T39 | 5634-5638 | Body_part | denotes | back | http://purl.org/sig/ont/fma/fma25056 |
T40 | 5694-5709 | Body_part | denotes | left lower lobe | http://purl.org/sig/ont/fma/fma7371 |
T41 | 5815-5820 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T42 | 5848-5863 | Body_part | denotes | left lower lobe | http://purl.org/sig/ont/fma/fma7371 |
T43 | 5993-6008 | Body_part | denotes | left lower lobe | http://purl.org/sig/ont/fma/fma7371 |
T44 | 6143-6158 | Body_part | denotes | left lower lobe | http://purl.org/sig/ont/fma/fma7371 |
T45 | 6380-6395 | Body_part | denotes | left lower lobe | http://purl.org/sig/ont/fma/fma7371 |
T46 | 6498-6514 | Body_part | denotes | left lower lobes | http://purl.org/sig/ont/fma/fma7371 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T20 | 2335-2339 | Body_part | denotes | lobe | http://purl.obolibrary.org/obo/UBERON_3010752 |
T21 | 2403-2407 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T22 | 2408-2412 | Body_part | denotes | lobe | http://purl.obolibrary.org/obo/UBERON_3010752 |
T23 | 3781-3785 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T24 | 3845-3849 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T25 | 4734-4750 | Body_part | denotes | Pleural effusion | http://purl.obolibrary.org/obo/UBERON_0000175 |
T26 | 4905-4909 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T27 | 5173-5190 | Body_part | denotes | pleural effusions | http://purl.obolibrary.org/obo/UBERON_0000175 |
T28 | 5705-5709 | Body_part | denotes | lobe | http://purl.obolibrary.org/obo/UBERON_3010752 |
T29 | 5859-5863 | Body_part | denotes | lobe | http://purl.obolibrary.org/obo/UBERON_3010752 |
T30 | 6004-6008 | Body_part | denotes | lobe | http://purl.obolibrary.org/obo/UBERON_3010752 |
T31 | 6154-6158 | Body_part | denotes | lobe | http://purl.obolibrary.org/obo/UBERON_3010752 |
T32 | 6391-6395 | Body_part | denotes | lobe | http://purl.obolibrary.org/obo/UBERON_3010752 |
T33 | 6867-6871 | Body_part | denotes | lobe | http://purl.obolibrary.org/obo/UBERON_3010752 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T36 | 42-50 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T37 | 1123-1131 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T38 | 1519-1527 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T39 | 2439-2447 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T40 | 2764-2772 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T41 | 3883-3891 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T42 | 4787-4802 | Disease | denotes | Lymphadenopathy | http://purl.obolibrary.org/obo/MONDO_0005833 |
T43 | 5208-5223 | Disease | denotes | lymphadenopathy | http://purl.obolibrary.org/obo/MONDO_0005833 |
T44 | 5508-5516 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T45 | 5517-5526 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T65 | 637-638 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T66 | 794-795 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T67 | 1239-1242 | http://purl.obolibrary.org/obo/CLO_0053001 | denotes | 114 |
T68 | 1315-1317 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T69 | 1817-1819 | http://purl.obolibrary.org/obo/CLO_0001236 | denotes | 2a |
T70 | 2007-2008 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T71 | 2322-2323 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T72 | 2351-2352 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T73 | 2403-2407 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T74 | 2403-2407 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T75 | 2655-2657 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T76 | 3352-3353 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T77 | 3414-3415 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T78 | 3506-3507 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T79 | 3781-3785 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T80 | 3781-3785 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T81 | 3845-3849 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T82 | 3845-3849 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T83 | 4038-4040 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T84 | 4734-4750 | http://purl.obolibrary.org/obo/UBERON_0000175 | denotes | Pleural effusion |
T85 | 4905-4909 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T86 | 4905-4909 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T87 | 5034-5036 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T88 | 5052-5054 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T89 | 5173-5190 | http://purl.obolibrary.org/obo/UBERON_0000175 | denotes | pleural effusions |
T90 | 5535-5539 | http://purl.obolibrary.org/obo/CLO_0001599 | denotes | A 54 |
T91 | 5572-5573 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T92 | 5681-5682 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T93 | 5755-5758 | http://purl.obolibrary.org/obo/CLO_0002755 | denotes | d–f |
T94 | 5777-5778 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T95 | 5815-5820 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T96 | 6060-6062 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T97 | 6203-6207 | http://purl.obolibrary.org/obo/CLO_0001568 | denotes | A 24 |
T98 | 6238-6239 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T99 | 6340-6343 | http://purl.obolibrary.org/obo/CLO_0051456 | denotes | a–e |
T100 | 6686-6688 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T29 | 4934-4936 | Chemical | denotes | SD | http://purl.obolibrary.org/obo/CHEBI_74807 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T35 | 4073-4092 | Phenotype | denotes | Pulmonary opacities | http://purl.obolibrary.org/obo/HP_0031457 |
T36 | 4734-4750 | Phenotype | denotes | Pleural effusion | http://purl.obolibrary.org/obo/HP_0002202 |
T37 | 4787-4802 | Phenotype | denotes | Lymphadenopathy | http://purl.obolibrary.org/obo/HP_0002716 |
T38 | 5173-5190 | Phenotype | denotes | pleural effusions | http://purl.obolibrary.org/obo/HP_0002202 |
T39 | 5208-5223 | Phenotype | denotes | lymphadenopathy | http://purl.obolibrary.org/obo/HP_0002716 |
T40 | 5517-5526 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T41 | 5612-5617 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T42 | 5619-5624 | Phenotype | denotes | cough | http://purl.obolibrary.org/obo/HP_0012735 |
T43 | 5630-5643 | Phenotype | denotes | low back pain | http://purl.obolibrary.org/obo/HP_0003419 |
T44 | 6278-6283 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T45 | 6288-6293 | Phenotype | denotes | cough | http://purl.obolibrary.org/obo/HP_0012735 |
T46 | 6880-6890 | Phenotype | denotes | atoll sign | http://purl.obolibrary.org/obo/HP_0032983 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T124 | 0-50 | Sentence | denotes | Evolution of CT findings in patients with COVID-19 |
T125 | 52-104 | Sentence | denotes | Evolution of CT characteristics of pulmonary lesions |
T126 | 105-219 | Sentence | denotes | Figure 1 depicts the evolution of CT features of pulmonary lesions in different time intervals from disease onset. |
T127 | 220-636 | Sentence | denotes | Significant differences were found among the time intervals in the proportion of pulmonary lesions that are (1) pure GGO (χ2 = 37.97, p = 0.01), (2) mixed attenuation (GGO and consolidation) (χ2 = 12.80, p < 0.01), (3) mixed attenuation with reticular/linear opacities (χ2 = 20.57, p < 0.01), and (4) consolidation with reticular/linear opacities (χ2 = 32.49, p < 0.01) and pure consolidation (χ2 = 10.37, p = 0.03). |
T128 | 637-1045 | Sentence | denotes | A significant linear decrease in the proportions of pure GGO lesions (y = 0.55–0.08x, p < 0.01) and mixed attenuation lesions (y = 0.31–0.03x, p = 0.01) and a significant linear increase in the proportions of lesion with reticular/linear opacities (mixed attenuation + linear opacities (y = 0.08 + 0.04x, p < 0.01) and consolidation + linear opacities (y = − 0.03 + 0.04x, p < 0.01)) were observed over time. |
T129 | 1046-1132 | Sentence | denotes | Fig. 1 Evolution of CT characteristics of pulmonary lesions in patients with COVID-19. |
T130 | 1133-1380 | Sentence | denotes | The time intervals after disease onset (days) were divided into 5 groups, i.e., days 0–3 (lesion number = 114), days 4–7 (lesion number = 241), days 8–10 (lesion number = 189), days 11–14 (lesion number = 178), and days 15–21 (lesion number = 95). |
T131 | 1381-1468 | Sentence | denotes | GGO, ground glass opacities; mixed attenuation = ground glass opacities + consolidation |
T132 | 1470-1527 | Sentence | denotes | Evolution of lobar distribution in patients with COVID-19 |
T133 | 1528-1706 | Sentence | denotes | No statistically significant difference was found in the lobar distribution of pulmonary findings over different time intervals from symptom onset, but some trends were observed. |
T134 | 1707-1821 | Sentence | denotes | For example, the proportion of patients with fewer than 3 lobes affected decreased in the first 10 days (Fig. 2a). |
T135 | 1822-1932 | Sentence | denotes | The proportion of patients with three or more affected lobes was higher in all of the time intervals analyzed. |
T136 | 1933-2147 | Sentence | denotes | Bilateral involvement was more prevalent than unilateral involvement with a trend toward an increase in the proportion of patients with bilateral CT abnormalities in the first 2 weeks after disease onset (Fig. 2b). |
T137 | 2148-2274 | Sentence | denotes | Lower lobes have higher rates of involvement than the others, but the differences are not statistically significant (Fig. 2c). |
T138 | 2275-2483 | Sentence | denotes | Fig. 2 Evolution of lobar distribution of the (a) number of lobe affected, (b) unilateral and bilateral lobes affected, and (c) lung lobe affected in patients with COVID-19 within 21 days after disease onset. |
T139 | 2484-2720 | Sentence | denotes | The time after disease onset (day) is categorized as 5 groups, i.e., days 0–3 (patient number = 37), days 4–7 (patient number = 69), days 8–10 (patient number = 53), days 11–14 (patient number = 49), and days 15–21 (patient number = 25) |
T140 | 2722-2772 | Sentence | denotes | Evolution of CT findings in patients with COVID-19 |
T141 | 2773-2834 | Sentence | denotes | The initial CTs of 4 out of 88 (4.5%) patients were negative. |
T142 | 2835-2958 | Sentence | denotes | Two of these four patients had their baseline CT during days 1–3, one during days 4–7, and one during days 8–10 of disease. |
T143 | 2959-3085 | Sentence | denotes | Subsequently, CT images of one patient remained negative even during days 8–10, and other patients developed CT abnormalities. |
T144 | 3086-3351 | Sentence | denotes | There were significant differences between the time interval groups after disease onset in proportions of patients with both GGO and consolidation (χ2 = 22.2, p < 0.01) and the combination of GGO, consolidation, and linear opacities (χ2 = 21.5, p < 0.01) (Table 2). |
T145 | 3352-3681 | Sentence | denotes | A proportion of patients with GGO and consolidation presented a decreasing trend during the 21 days after disease onset (y = 0.48–0.09x, p < 0.01), while a proportion of patient with all three findings including ground glass opacities, consolidation, and linear opacities presented an increasing trend (y = 0.12–0.11x, p < 0.01). |
T146 | 3682-3801 | Sentence | denotes | No significant difference was found in the proportions of patients with other CT findings or total lung severity score. |
T147 | 3802-3926 | Sentence | denotes | Table 2 Evolution of CT findings and total lung severity scores of patients with COVID-19 within 21 days after disease onset |
T148 | 3927-3977 | Sentence | denotes | Characteristic Time after disease onset χ2 p value |
T149 | 3978-4072 | Sentence | denotes | Days 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25) |
T150 | 4073-4092 | Sentence | denotes | Pulmonary opacities |
T151 | 4093-4156 | Sentence | denotes | GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16 |
T152 | 4157-4238 | Sentence | denotes | GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 < 0.01 |
T153 | 4239-4315 | Sentence | denotes | GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76 |
T154 | 4316-4386 | Sentence | denotes | Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74 |
T155 | 4387-4471 | Sentence | denotes | Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19 |
T156 | 4472-4576 | Sentence | denotes | GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 < 0.01 |
T157 | 4577-4639 | Sentence | denotes | Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36 |
T158 | 4640-4654 | Sentence | denotes | Other findings |
T159 | 4655-4731 | Sentence | denotes | Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36 |
T160 | 4732-4784 | Sentence | denotes | Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – – |
T161 | 4785-4836 | Sentence | denotes | Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – – |
T162 | 4837-4898 | Sentence | denotes | Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72 |
T163 | 4899-4924 | Sentence | denotes | Total lung severity score |
T164 | 4925-4993 | Sentence | denotes | Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29 |
T165 | 4994-5059 | Sentence | denotes | Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – – |
T166 | 5060-5098 | Sentence | denotes | Numbers in parentheses are percentages |
T167 | 5099-5147 | Sentence | denotes | n number of patients, GGO ground glass opacities |
T168 | 5148-5252 | Sentence | denotes | None of the patients had pleural effusions or intrathoracic lymphadenopathy during the follow-up period. |
T169 | 5253-5436 | Sentence | denotes | Some of the patients had cavitation on CT, but these are thought to represent pre-existing conditions as none of the patients in the study cohort developed cavitation on follow-up CT. |
T170 | 5437-5527 | Sentence | denotes | Figures 3 and 4 show the evolution of CT findings of two patients with COVID-19 pneumonia. |
T171 | 5528-5723 | Sentence | denotes | Fig. 3 A 54-year-old woman with exposure to a COVID-infected patient presented with fever, cough, and low back pain for 2 days and remains hospitalized. a–c CT shows left lower lobe GGO on day 2. |
T172 | 5724-5821 | Sentence | denotes | The total severity score is 1. d–f CT on day 7 shows a significant increase in GGO in both lungs. |
T173 | 5822-5869 | Sentence | denotes | The severity score of the left lower lobe is 2. |
T174 | 5870-5966 | Sentence | denotes | The total severity score is 5. g–i CT on day 9 shows bilateral GGO and subpleural consolidation. |
T175 | 5967-6014 | Sentence | denotes | The severity score of the left lower lobe is 3. |
T176 | 6015-6116 | Sentence | denotes | The total severity score is 9. j–l CT on day 11 shows diffuse GGO and linear opacities (thick arrow). |
T177 | 6117-6164 | Sentence | denotes | The severity score of the left lower lobe is 4. |
T178 | 6165-6195 | Sentence | denotes | The total severity score is 12 |
T179 | 6196-6419 | Sentence | denotes | Fig. 4 A 24-year-old man with exposure to a COVID-infected patient presented with fever and cough for 1 day and remains hospitalized currently. a–e CT scan shows GGO in the subpleural left lower lobe on day 1 (thick arrow). |
T180 | 6420-6529 | Sentence | denotes | The overall total severity score is 1. f–j CT on day 4 shows enlarging GGO in left lower lobes (thick arrow). |
T181 | 6530-6630 | Sentence | denotes | The overall total severity score is 3. k–o CT on day 8 shows increased GGO in bilateral lower lobes. |
T182 | 6631-6763 | Sentence | denotes | The total severity score was 5. p–t CT obtained on day 11 shows bilateral ground glass opacities and linear opacities (thick arrow). |
T183 | 6764-6905 | Sentence | denotes | The overall total severity score was 7. u–y CT obtained on day 15 shows improvement of bilateral lower lobe GGO and atoll sign (thick arrow). |
T184 | 6906-6943 | Sentence | denotes | The overall total severity score is 5 |